We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+1.41%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$274M
AUM Growth
+$79.4M
Cap. Flow
+$63.1M
Cap. Flow %
23.07%
Top 10 Hldgs %
74.6%
Holding
47
New
11
Increased
13
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$7.36M
2
VTRS icon
Viatris
VTRS
+$5.82M
3
MDRX
Veradigm Inc. Common Stock
MDRX
+$3.81M
4
RDNT icon
RadNet
RDNT
+$2.42M
5
SNY icon
Sanofi
SNY
+$2.19M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$5.54M
2
ALKS icon
Alkermes
ALKS
+$5.45M
3
LNTH icon
Lantheus
LNTH
+$5.35M
4
PCRX icon
Pacira BioSciences
PCRX
+$3.58M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.86M

Sector Composition

Rank Sector Weight
1 Healthcare 47.9%
2 Consumer Staples 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRC icon
26
AtriCure
ATRC
$1.92B
$1.67M 0.61%
40,376
-9,624
-19% -$399K
UTHR icon
27
United Therapeutics
UTHR
$25.8B
$1.34M 0.49%
+6,000
New +$1.48M
FENC icon
28
Fennec Pharmaceuticals
FENC
$332M
$1.24M 0.45%
149,200
-63,800
-30% -$592K
SLGC
29
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$1.21M 0.44%
475,000
+225,000
+90% +$645K
MCK icon
30
McKesson
MCK
$100B
$1.07M 0.39%
+3,000
New +$1.08M
SEM
31
DELISTED
Select Medical
SEM
$646K 0.24%
+46,400
New +$683K
OLK
32
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$642K 0.23%
+28,500
New +$621K
MXCT icon
33
MaxCyte
MXCT
$112M
$495K 0.18%
100,000
– –
ICUI icon
34
ICU Medical
ICUI
$4.21B
$495K 0.18%
3,000
-2,000
-40% -$344K
BIO icon
35
Bio-Rad Laboratories Class A
BIO
$8.71B
$479K 0.18%
+1,000
New +$468K
PCRX icon
36
Pacira BioSciences
PCRX
$1.04B
$408K 0.15%
10,000
-90,000
-90% -$3.58M
NSTG
37
DELISTED
NanoString Technologies, Inc.
NSTG
$248K 0.09%
25,000
-5,000
-17% -$49.5K
TECH icon
38
Bio-Techne
TECH
$11.2B
$74.2K 0.03%
+1,000
New +$77.1K
SLGCW
39
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$51K 0.02%
+20,000
New +$8.79K
BDX icon
40
PUT
Becton Dickinson
BDX
$45.6B
– –
-25,000
Closed -$6.36M
BIIB icon
41
Biogen
BIIB
$30B
– –
-20,000
Closed -$5.54M
CDNA icon
42
CareDx
CDNA
$2.26B
– –
-30,000
Closed -$342K
LNTH icon
43
Lantheus
LNTH
$6.49B
– –
-105,000
Closed -$5.35M
MRK icon
44
Merck
MRK
$322B
– –
-25,000
Closed -$2.77M
PLXS icon
45
Plexus
PLXS
$6.72B
– –
-15,500
Closed -$1.6M
TPB icon
46
Turning Point Brands
TPB
$1.45B
– –
-125,000
Closed -$2.7M
SLGC
47
CALL
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-20,000
Closed -$50.2K
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q1 2023 Portfolio in Review

As of Q1 2023, Tamarack Advisers held 47 positions worth $274M, up 41% from $194M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Tamarack Advisers deployed $63.1M of net new capital in Q1 2023, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was Amgen: 30,000 shares worth $7.25M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 69% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Alkermes, an estimated $5.45M trimmed.

  • Tamarack Advisers's largest Q1 2023 buy was Amgen: 30,000 shares worth $7.25M.
  • Tamarack Advisers added most to Viatris in Q1 2023, an estimated $5.82M increase.
  • Tamarack Advisers's biggest Q1 2023 reduction was Alkermes, cutting an estimated $5.45M.
  • Tamarack Advisers fully exited Biogen in Q1 2023, selling an estimated $5.54M.
  • Tamarack Advisers's ten largest holdings make up 75% of its $274M portfolio in Q1 2023.
  • Tamarack Advisers opened 11 new positions and closed 8 in Q1 2023.
  • Tamarack Advisers's portfolio value rose 41% quarter-over-quarter to $274M.

Based on Tamarack Advisers's 13F filing for Q1 2023, filed 11 May 2023.